CA2580679A1 - Variants and chemically-modified variants of phenylalanine ammonia-lyase - Google Patents

Variants and chemically-modified variants of phenylalanine ammonia-lyase Download PDF

Info

Publication number
CA2580679A1
CA2580679A1 CA002580679A CA2580679A CA2580679A1 CA 2580679 A1 CA2580679 A1 CA 2580679A1 CA 002580679 A CA002580679 A CA 002580679A CA 2580679 A CA2580679 A CA 2580679A CA 2580679 A1 CA2580679 A1 CA 2580679A1
Authority
CA
Canada
Prior art keywords
pal
protein
peg
activity
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002580679A
Other languages
English (en)
French (fr)
Inventor
Alejandra Gamez
Lin Wang
Woomi Kim
Mary Straub
Marianne G. Patch
Emil Kakkis
Dan Oppenheimer
Paul A. Fitzpatrick
Robert Heft
Raymond C. Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Biomarin Pharmaceutical Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2580679A1 publication Critical patent/CA2580679A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CA002580679A 2004-09-17 2005-09-19 Variants and chemically-modified variants of phenylalanine ammonia-lyase Abandoned CA2580679A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61077004P 2004-09-17 2004-09-17
US60/610,770 2004-09-17
US65195005P 2005-02-09 2005-02-09
US60/651,950 2005-02-09
PCT/US2005/033895 WO2006034373A2 (en) 2004-09-17 2005-09-19 Variants and chemically-modified variants of phenylalanine ammonia-lyase

Publications (1)

Publication Number Publication Date
CA2580679A1 true CA2580679A1 (en) 2006-03-30

Family

ID=36090659

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002580679A Abandoned CA2580679A1 (en) 2004-09-17 2005-09-19 Variants and chemically-modified variants of phenylalanine ammonia-lyase

Country Status (6)

Country Link
US (1) US7553653B2 (enExample)
EP (1) EP1814984A2 (enExample)
JP (1) JP2008513027A (enExample)
AU (1) AU2005286763A1 (enExample)
CA (1) CA2580679A1 (enExample)
WO (1) WO2006034373A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06005451A (es) 2003-11-17 2007-01-26 Biomarin Pharm Inc Metodos y composiciones para el tratamiento de trastornos metabolicos.
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008070117A1 (en) * 2006-12-04 2008-06-12 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
CA2682598C (en) 2007-04-11 2016-06-07 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US20110201022A1 (en) * 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
WO2010104959A1 (en) * 2009-03-11 2010-09-16 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
CA2755047C (en) * 2009-03-11 2018-12-04 Promedior, Inc. Treatment methods for autoimmune disorders
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
AU2010262847B2 (en) 2009-06-17 2016-06-02 Promedior, Inc. SAP variants and their use
SI3025728T1 (sl) 2010-02-04 2018-11-30 Biomarin Pharmaceutical Inc. Metoda za čiščenje prokariontskih fenilalanin amonij-liaznih variant
CN105061534A (zh) 2010-09-22 2015-11-18 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
HK1203075A1 (en) 2011-12-22 2015-10-16 艾丽奥斯生物制药有限公司 Substituted phosphorothioate nucleotide analogs
EP2828277A1 (en) 2012-03-21 2015-01-28 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EP2877584A4 (en) 2012-07-26 2016-03-30 Casa Luker S A METHODS FOR INCREASING THE PRODUCTION OF PHENOLIC COMPOUNDS FROM THEBROMA COCOA
ES2890955T3 (es) 2013-04-18 2022-01-25 Codexis Inc Polipéptidos de fenilalanina amoníaco liasa modificados
CA2943432A1 (en) 2014-04-16 2015-10-22 Codexis, Inc. Engineered tyrosine ammonia lyase
CA2985819A1 (en) 2015-05-13 2016-11-17 Synlogic, Inc. Bacteria engineered to reduce hyperphenylalaninemia
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3807409A4 (en) 2018-06-12 2022-08-03 Codexis, Inc. Engineered tyrosine ammonia lyase
US11198861B2 (en) 2018-07-12 2021-12-14 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
JP2022513199A (ja) 2018-12-14 2022-02-07 コデクシス, インコーポレイテッド 操作されたチロシンアンモニアリアーゼ
KR20220103944A (ko) * 2019-10-17 2022-07-25 이케나 온콜로지, 인코포레이티드 Peg화 키뉴레니나제 효소 및 암 치료를 위한 그의 용도
BR112022015139A2 (pt) 2020-02-04 2022-10-11 Codexis Inc Polipeptídeo da leucina descarboxilase engenheirada, composição, sequência de polinucleotídeo engenheirado, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo da leucina descarboxilase engenheirada e para tratar e/ou prevenir os sintomas de doença da urina de xarope de bordo, composição, e, uso
JP2023518184A (ja) * 2020-03-20 2023-04-28 シンロジック オペレーティング カンパニー インコーポレイテッド 高フェニルアラニン血症を軽減するように遺伝子改変された微生物
JP2023539632A (ja) 2020-08-28 2023-09-15 コデクシス, インコーポレイテッド 操作されたプロテアーゼバリアント
CA3191900A1 (en) 2020-08-28 2022-03-03 Codexis, Inc. Engineered amylase variants
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
US20250108095A1 (en) * 2023-09-28 2025-04-03 Aperiam Bio, Inc. Degradation of toxins in vivo

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562151A (en) * 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
DK75593D0 (enExample) * 1993-06-25 1993-06-25 Novo Nordisk As
US5981239A (en) * 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) * 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) * 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
AU772153B2 (en) * 1999-02-12 2004-04-08 Molecular Insight Pharmaceuticals, Inc. Matrices for drug delivery and methods for making and using the same
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
EP1280924A2 (en) * 2000-04-14 2003-02-05 University of South Carolina Research Foundation Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
US6967097B2 (en) * 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
KR20040088538A (ko) 2002-02-26 2004-10-16 이 아이 듀폰 디 네모아 앤드 캄파니 유전 인자의 재조합 방법
CA2506026A1 (en) 2002-11-14 2004-05-27 The Scripps Research Institute Crystalline form of fatty acid amine hydrolase (faah)

Also Published As

Publication number Publication date
US20070048855A1 (en) 2007-03-01
WO2006034373A2 (en) 2006-03-30
EP1814984A2 (en) 2007-08-08
WO2006034373A3 (en) 2006-11-02
WO2006034373A8 (en) 2006-08-10
JP2008513027A (ja) 2008-05-01
US7553653B2 (en) 2009-06-30
WO2006034373A9 (en) 2006-05-11
AU2005286763A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
CA2580679A1 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
US6546074B1 (en) Protein crystal structure and method for identifying protein modulators
WO2001083769A2 (en) Crystallization of 4-diphosphocytidyl-2-c-methylerythritol synthesis
WO2003012089A2 (en) Crystal structure of beta-site app cleaving enzyme (bace) and use thereof
AU6960696A (en) Crystalline zap family proteins
WO2001085748A2 (en) Designing modulators for glycosyltransferases
WO2012097826A2 (en) Crystal structure of a type ib p-type atpase
CA2615753A1 (en) Crystal structure of human soluble adenylate cyclase
WO2009076621A1 (en) High resolution structures of acidic mammalian chitinases and uses thereof
AU2007204226B2 (en) ACE N-domain crystal
WO2012037150A1 (en) Crystal structures of o-glcnac transferase and uses thereof
US20040157309A1 (en) Crystalline form of the catalytic domain of ADAM33 and methods of use thereof
WO2008142366A2 (en) Methods for selecting or designing modulators, based on the crystal structure of leukotriene c4 synthase (ltc4s)
CN1993379A (zh) 抗il-13抗体、抗il-13抗体的晶体以及包含它们的复合物
CA2349410A1 (en) Crystallized form of fc epsilon receptor alpha chain, its 3-d model and uses thereof
GB2373504A (en) AMP deaminase crystal structure
CA2454572A1 (en) Crystalline pde4d2 catalytic domain complex, and methods for making and employing same
WO2004078910A2 (en) Identifying inhibitors of type ii isopentenyl diphosphate: dimethylallyl diphosphate isomerase
US20040116659A1 (en) Helicase inhibitors
EP1546315A1 (en) Atomic structure of the catalytic domain for use in designing and identifying inhibitors of zap-70 kinase
CA2982386A1 (en) Crystal structure of staphylococcus aureus autolysin e, method of producing the crystal and its use in screening methods
MXPA05012919A (en) CRYSTALLOGRAPHIC STRUCTURE OF TcPRACA AND USES THEREFOR
HK1120557A (en) Crystal structure of human soluble adenylate cyclase
AU5660900A (en) Crystalline zap family proteins

Legal Events

Date Code Title Description
FZDE Discontinued